5300 MEMORIAL DRIVE, HOUSTON, TX
Election of Directors and Approval of Key Proposals at Moleculin Biotech
Investor Presentation
Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented
Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
Q2
Q1
Amended Annual Report
FY 2025
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration Statement for Securities
S-1
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence